All In Biotech

Drug Trial Radar · NCT06596876

A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations

A Randomized, Controlled, Double-blind, Double-dummy, Multicenter Phase III Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 165 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

165

Actual

Start

Nov 6, 2024

Primary completion

Jan 29, 2026

Study completion Jan 29, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a multicenter, randomized, double-blind, double-dummy, active-controlled, Phase III clinical study. The aim of this trial is to evaluated the efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's Disease With Motor Fluctuations.

Conditions

  • Parkinson's Disease

Interventions

  • HRG2010; Sustained-release Carbidopa/Levodopa administered placeboDrug

    Subjects will receive HRG2010 and Sustained-release Carbidopa/Levodopa administered placebo administered orally.

  • Sustained-release Carbidopa/Levodopa; HRG2010 placeboDrug

    Subjects will receive Sustained-release Carbidopa/Levodopa and HRG2010 placebo administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in "Off" time at Week 21Time frame: Last three days collected at the end of treatment period, at Week 21

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.